Introduction
============

Approximately 1,688,780 new cancer cases and 600,920 cancer deaths are projected to occur in the USA in 2017.[@b1-ott-11-851] Cancer is caused by uncontrolled cell division or inappropriate survival of a cell with DNA damage, which is critical for tumor initiation and progression.

Thousands of genes that are either transcriptionally upregulated or downregulated in tumor samples have been identified through microarray analysis, indicating that cancer is a disease with extreme heterogeneity. These deregulations act as the main drivers that enable tumors to invade cellular barriers, proliferate, and metastasize.[@b2-ott-11-851] The dynamic regulation of histone modifications in promoters and enhancers plays a vital role in the control of gene expression and consequently affects disease susceptibility. EZH2 has been widely investigated because it serves as a master regulator of cancer epigenetics.[@b3-ott-11-851] It is also a core component of Polycomb repressive complex 2, which mainly methylates lysine 27 of histone H3 (H3K27) to induce transcriptional gene silencing.[@b4-ott-11-851] EZH2 overexpression causes epigenetic alterations in tumor suppressor genes, and such changes are required for cancer proliferation, migration, invasion, and metastasis.[@b5-ott-11-851]--[@b7-ott-11-851] Therefore, aberrant EZH2 activities may participate in increasing the risk of tumorigenesis.

The oncogenic role of EZH2 has been observed in numerous cancers, including prostate cancer, bladder cancer, breast cancer, and melanoma, whose high EZH2 expression levels are positively correlated with poor survival rate and aggressiveness.[@b8-ott-11-851]--[@b11-ott-11-851] The function of EZH2 in cancer progression may also be affected by mutations. For example, the mutation of tyrosine 641 (Y641) within the C-terminal catalytic SET domain of EZH2 increases the levels of trim-ethylated H3K27 (H3K27me3) and thus represses the expression of Polycomb targets.[@b12-ott-11-851] The loss-of-function mutations of *EZH2* may occur during cancer development. The frequency of missense mutations of *EZH2* in the pediatric subtype of human T-cell acute lymphoblastic leukemia (T-ALL) and early T-cell precursor (ETP) ALL is higher than that in non-ETP pediatric T-ALL.[@b13-ott-11-851],[@b14-ott-11-851] Similarly, single nucleotide polymorphisms (SNPs) of *EZH2* may have different effects on disease susceptibility through the transcriptional regulation of genes involved in cancer initiation and progression ([Figure 1](#f1-ott-11-851){ref-type="fig"}). Although several studies have investigated the relationship of 4 SNPs (rs887569 C\>T, rs2302427 C\>G, rs3757441 T\>C, and rs41277434 A\>C) of *EZH2* and cancer risk, results are inconsistent. This relationship has yet to be systematically investigated, and definitive conclusions have yet to be presented. Hence, comprehensive reviews and meta-analyses should be performed. Here, we conducted a meta-analysis to precisely assess and provide a comprehensive conclusion about the associations between *EZH2* variations and cancer risk from all eligible case--control studies published to date.

Materials and methods
=====================

Search strategy and identification of eligible studies
------------------------------------------------------

Two reviewers (Ling and You) searched the online databases PubMed, Google Scholar, Web of Science, Embase, China National Knowledge Infrastructure (CNKI), and Wangfang Data to identify relevant articles published until September 2017. The following search terms were used either separately or in combination: "EZH2, enhancer of zeste homolog 2," "rs887569, rs2302427, rs3757441, rs41277434," "cancer, carcinoma, neoplasm," "tumor, tumour," and "SNP, polymorphism, allele, variation." Studies were limited to articles published in Chinese or English, and the references of pertinent articles were manually screened and checked. Articles that satisfied the following criteria were included: 1) studies that assessed the association between a SNP from EZH2 (rs887569, rs2302427, rs3757441, and rs41277434) and cancer risk; 2) case--control or population-based studies; and 3) studies with available genotype frequencies. Studies were excluded according to the following criteria: 1) articles that were presented as a systematic review or focusing on animals; 2) studies that involved DNA extracted from cancer tissues rather than blood samples, or studies that did not provide usable data for meta-analysis; and 3) studies that reported data overlapping with those described in the included studies.

Data extraction
---------------

Two reviewers (Ling and You) independently extracted the following information from each study: first author, year of publication, cancer types, country or region, ethnicity, genotype detection method, control source of each study, number of cases and controls, polymorphism site included in each study, and results of Hardy--Weinberg equilibrium (HWE). Inconsistencies were resolved by discussion until a consensus was obtained. Newcastle--Ottawa Quality Assessment Scale was used to examine the quality of the articles included in this study.[@b15-ott-11-851]

Statistical analysis
--------------------

The strength of the association between SNPs and cancer risk was evaluated by determining the odds ratio (OR) with 95% CI, which was calculated by *Z*-test, and the result of the pooled OR was considered significant when *P*\<0.05. This association was also examined by using homozygote, heterozygote, dominant genetic, and recessive genetic models. Subgroup analyses were conducted according to cancer types and ethnic groups. Heterogeneity between articles was identified with *Q*-test and *I*^2^ index.[@b16-ott-11-851] When heterogeneity was observed (*P*\<0.05 or *I*^2^\>50%), a random-effect model (DerSimonian--Laird method) was applied; otherwise, a fixed-effect model (Mantel--Haenszel method) was utilized.[@b17-ott-11-851],[@b18-ott-11-851] Publication bias was evaluated by Egger's test and Begg's test, with a *P*-value \>0.05 considered evidence for no potential publication bias. Begg's or Egger's test was performed only for SNPs involved in 5 or more studies. Statistical tests were 2-sided, and analyses were carried out with Stata 12.0 at least twice.

Results
=======

Characteristics of the included studies
---------------------------------------

After PubMed, Google Scholar, Web of Science, Embase, CNKI, and Wangfang Data online databases were extensively screened, 216 relevant articles were identified. As shown in the flowchart in [Figure 2](#f2-ott-11-851){ref-type="fig"}, 12 case--control studies involving the 4 EZH2 SNPs were finally included for further meta-analysis after ineligible articles were excluded according to our inclusion and exclusion criteria.[@b19-ott-11-851]--[@b30-ott-11-851] The characteristics of the included studies are summarized in [Table 1](#t1-ott-11-851){ref-type="table"}. Of the 12 included studies, 6 focused on digestive system cancers (DSCs; gastric cancer, hepatocellular carcinoma, colorectal cancer \[CRC\], and esophageal squamous cell carcinoma), 4 examined urogenital system cancers (USCs; prostate cancer, urothelial cell carcinoma, and bladder cancer), and 2 investigated other types of cancers. The detailed information of the analyzed articles for each SNP is shown in [Table S1](#SD4-ott-11-851){ref-type="supplementary-material"}.

Quantitative synthesis
----------------------

The associations between *EZH2* SNPs and human cancer risks were evaluated ([Table 2](#t2-ott-11-851){ref-type="table"}; [Figures 3](#f3-ott-11-851){ref-type="fig"} and [4](#f4-ott-11-851){ref-type="fig"}). Overall, the *EZH2* rs887569 C\>T polymorphism was significantly associated with a decreased cancer risk in the dominant and recessive models (CTTT/CC: OR =0.849, 95% CI: \[0.740 to 0.973\], *P*=0.019; TT/CCCT: OR =0.793, 95% CI: \[0.654 to 0.962\], *P*=0.019). EZH2 rs2302427 C\>G polymorphism was also related to the decreased overall cancer risk in the homozygote dominant genetic and recessive genetic models (GG/CC: OR =0.562, 95% CI: \[0.400 to 0.792\], *P*=0.001; CGGG/CC: OR =0.856, 95% CI: \[0.748 to 0.980\], *P*=0.024; GG/CCCG: OR =0.733, 95% CI: \[0.571 to 0.940\], *P*=0.015). In other genotype models, such a relationship remains controversial.

Subgroup analysis revealed that the variant CG (OR =0.686, 95% CI: \[0.511 to 0.921\], *P*=0.012) and CG/GG (OR =0.688, 95% CI: \[0.515 to 0.917\], *P*=0.01) genotypes of rs2302427 C\>G polymorphism were associated with a decreased cancer risk compared with the wild-type CC genotype in individuals of Caucasian descent. rs2302427 C\>G polymorphism in Asian descent was linked to the decreased overall cancer risk in the homozygote and recessive genetic models (GG/CC: OR =0.550, 95% CI: \[0.384 to 0.787\], *P*=0.001; GG/CCCG: OR =0.731, 95% CI: \[0.566 to 0.944\], *P*=0.016).

We also conducted a stratified analysis of the data in terms of cancer types, namely, USCs and DSCs. With regard to subgroup analysis of USCs, our results did not show any association of rs887569 C\>T polymorphism with cancer risk in any genotype model. However, rs2302427 C\>G polymorphism was correlated with a decreased cancer risk in homozygote and recessive genetic models for DSCs. As for USCs, similar results were observed in homozygote, heterozygote, and dominant genetic models.

For rs3757441 T\>C and rs41277434 A\>C polymorphisms, 9 and 7 studies were included, respectively. No evidence suggested that these 2 SNPs might be associated with cancer risk either in overall or subgroup analysis (*P*\>0.05; [Table 2](#t2-ott-11-851){ref-type="table"}; [Figures S1](#SD1-ott-11-851){ref-type="supplementary-material"} and [S2](#SD2-ott-11-851){ref-type="supplementary-material"}).

Sensitivity analysis and publication bias assessment
----------------------------------------------------

Sensitivity analyses were conducted by omitting each individual article to measure its specific effect on the pooled ORs ([Figure S3](#SD3-ott-11-851){ref-type="supplementary-material"}). The sensitivity analysis forest plot indicated that no single study significantly affected the pooled ORs for any genetic models of the 4 SNPs. A random-effect model was used when obvious heterogeneity was observed (*P*\<0.05 or *I*^2^\>50%); otherwise, a fixed-effect model was applied. Considering the small number of studies included in the meta-analysis, we conducted Begg's and Egger's tests to assess the publication bias for each genetic model of the 4 SNPs. No evidence of publication bias was detected in any of the homozygote, heterozygote, and dominant and recessive models of each SNP except rs3757441 and rs41277434 ([Table 3](#t3-ott-11-851){ref-type="table"}).

Discussion
==========

EZH2 overexpression is a marker of advanced and metastatic diseases in many solid tumors, including prostate,[@b8-ott-11-851] bladder,[@b31-ott-11-851] gastric,[@b32-ott-11-851] lung,[@b33-ott-11-851] and breast cancer.[@b34-ott-11-851] EZH2 has also been implicated in cancer initiation, promotion, and progression.[@b35-ott-11-851] Therefore, genetic mutations may significantly influence the function of EZH2 in cancer initiation and risk.[@b36-ott-11-851] Cumulative studies have suggested that recurrent heterozygous point mutations affecting tyrosine 641 (Y641) in germinal center B-cell and point mutations at alanine 687 or 677 in non-Hodgkin's lymphomas can increase H3K27me3 levels, thereby repressing the expression of Polycomb targets.[@b37-ott-11-851]--[@b39-ott-11-851]

SNPs, as the most common genetic sequence variation, can affect the function of *EZH2* and its downstream targets by altering *EZH2* transcription and H3K27 trimethylation. For example, the rs3757441 polymorphism C/C genotype is associated with strong EZH2 and H3K27me3 immunoreactivity in primary CRC, indicating that this genotype can be a promising biomarker for EZH2-targeting agents.[@b27-ott-11-851] The rs887569 TT genotype is correlated with a significantly increased overall survival and a reduced risk of mortality in patients with cholangiocarcinoma.[@b40-ott-11-851] Zhou et al[@b22-ott-11-851] found that the haplotypes of *EZH2* genes with minor alleles of rs12670401 and rs6464926 or major alleles of rs2072407, rs734005, and rs734004 significantly increase the risk of gastric cancer, whereas the haplotypes of *EZH2* genes with major alleles of rs12670401 and rs6464926 or minor alleles of rs2072407, rs734005, and rs734004 can reduce the risk of gastric cancer. These studies have demonstrated that the SNPs of *EZH2* are closely related to cancer risk and prognosis. Although studies have revealed that *EZH2* polymorphisms are associated with cancer risk, results are inconsistent. Therefore, we systematically reviewed the literature through a meta-analysis of the association between *EZH2* gene polymorphisms and cancer risk. To the best of our knowledge, this study is the first meta-analysis to investigate the relationship between *EZH2* SNPs and cancer risk.

While searching for eligible studies, we found 11 *EZH2* SNPs that were reported to be associated with cancer risk: rs887569, rs2302427, rs375441, rs41277434, rs6950683, rs2072407, rs734005, rs734004, rs6464926, rs12670401, and rs1880357. However, only the first 4 SNPs were examined in at least 5 individual studies. We then performed 4 genotype distributions between cases and controls. Our study included 5 articles, with a pooled total of 1,794 cases and 1,878 controls, which were relevant to the relationship between the rs887569 SNP and cancer risk. The cancer risk was significantly reduced in CT/TT genotype relative to CC genotype (CTTT/CC: OR =0.849, 95% CI: \[0.740 to 0.973\], *P*=0.019). This association was also detected in the recessive genetic model (TT/CCCT: OR =0.793, 95% CI: \[0.654 to 0.962\], *P*=0.019). *Z*-scores and *P*-values were calculated to evaluate the reliability of our results, and the *P*-values of the dominant and recessive genetic models of rs887569 were 0.019, which might strengthen our findings. We also found a significant link between rs2302427 polymorphism and cancer susceptibility in the homozygote genotype, dominant genetic, and recessive genetic models (GG/CC: OR =0.562, 95% CI: \[0.400 to 0.792\], *P*=0.001; CGGG/CC: OR =0.856, 95% CI: \[0.748 to 0.980\], *P*=0.024; GG/CCCG: OR =0.733, 95% CI: \[0.571 to 0.940\], *P*=0.015). In the subgroup analysis of ethnicity, rs2302427 CG or CG/GG genotype was significantly related to a decreased prostate cancer risk in the Caucasian population, whereas the GG genotype was closely linked to a decreased overall cancer risk in the Asian population. However, the reliability of our data would have improved had we enrolled more eligible studies and a larger sample size than the obtained data.

We subsequently examined the effect of *EZH2* SNP rs3757441, which is a key indicator of poor prognosis in metastatic CRC, on overall cancer risk by analyzing 9 eligible studies.[@b27-ott-11-851] However, in our current meta-analysis, the association between rs3757441 and cancer risk is controversial. We also performed a stratified analysis by cancer types, but no association was observed between rs3757441 and USC or DSC. These inconsistent results might be due to the heterogeneity of cancer type, ethnicity, and sample size, considering that rs3757441 plays a protective role in lung cancer in a Korean population[@b21-ott-11-851] but acts as a risk factor in CRC in a Han Chinese population.[@b24-ott-11-851] Furthermore, we searched for articles related to *EZH2* rs41277434, and our results indicated that no significant association was found between rs41277343 and overall cancer risk or DSC risk.

Sensitivity analysis revealed that the results of our study were robust. Egger's and Begg's tests indicated a publication bias in homozygote and recessive models of rs3757441 and rs41277434. Future large-scale well-designed studies should be conducted to confirm the publication bias of the genetic models of rs375441 and rs41277434.

Several limitations of our meta-analysis should be considered. First, most of the eligible studies mainly focused on East Asian populations, whereas 2 studies involved Caucasians. Studies on other ethnicities were not included in this meta-analysis. Thus, our results were incomplete. The number of eligible studies and the sample size were relatively small and might consequently cause a type II error. Second, our results were based on unadjusted estimates because of the lack of original data on age, gender, and smoking status. Potential bias caused by these factors might also persist. Third, differences among various cancers might lead to heterogeneity when all cancer types were pooled. Stratified analysis by specific cancer type was not conducted because of the insufficient number of studies on single cancer type. Finally, we only searched for publications in Chinese and English. As such, language restriction would limit our sample size.

Conclusion
==========

Despite the limitations, our meta-analysis revealed that *EZH2* rs887569 and rs2302427 might be correlated with a decreased cancer risk in specific genetic models, whereas the association of *EZH2* rs3757441 and rs41277434 polymorphisms with overall cancer risk was not observed. To confirm our results and provide highly reliable evidence supporting these associations, we recommend future large-scale and well-designed studies on diverse ethnic populations and cancer types.

Supplementary materials
=======================

###### 

Forest plot for the relationship between rs3757441 and cancer risk: (**A**) CT/TT; (**B**) CC/TT; (**C**) CCCT/TT; (**D**) CC/CTTT.

**Note:** Weights are from random effects analysis.

###### 

Forest plot for the relationship between rs41277434 and cancer risk: (**A**) AC/AA; (**B**) CC/AA; (**C**) ACCC/AA; (**D**) CC/AAAC.

###### 

Forest plot of sensitivity analysis for EZH2 SNPs.

**Abbreviation:** SNP, single nucleotide polymorphism.

###### 

Characteristics of eligible studies for each SNP in the meta-analysis

  Gene     Reference                         Years   Cancer type                       Region    Ethnicity   Controls   NOS   Genotype-case   Genotype-control   Method   HWE *P*-value                          
  -------- --------------------------------- ------- --------------------------------- --------- ----------- ---------- ----- --------------- ------------------ -------- --------------- ----- ----- ---------- ---------
  *EZH2*   Rs887569 C\>T                                                                                                      CC              CT                 TT       CC              CT    TT               
           Huang et al[@b49-ott-11-851]      2015    Colorectal cancer                 China     Asian       PB         8     10              47                 39       16              43    41    PCR-RFLP   0.41
           Wang et al[@b46-ott-11-851]       2014    Colorectal cancer                 China     Asian       HB         7     237             239                36       221             266   59    PCR-RFLP   0.11
           Ma et al[@b48-ott-11-851]         2014    Esophageal squamous cell cancer   China     Asian       HB         7     126             253                97       129             264   99    PCR-RFLP   0.09
           Yoon et al[@b43-ott-11-851]       2010    Lung cancer                       Korea     Asian       PB         8     159             144                32       148             145   42    Illumina   0.49
           Chang et al[@b52-ott-11-851]      2016    Bladder cancer                    China     Asian       PB         8     180             171                24       150             182   43    PCR-RFLP   0.27
  *EZH2*   Rs2302427 C\>G                                                                                                     CC              CG                 GG       CC              CG    GG               
           Yu et al[@b45-ott-11-851]         2013    Hepatocellular carcinoma          Taiwan    Asian       HB         7     135             75                 10       346             171   35    TaqMan     0.03
           Yoon et al[@b43-ott-11-851]       2010    Lung cancer                       Korea     Asian       PB         8     284             49                 2        282             50    3     Illumina   0.64
           Yu et al[@b47-ott-11-851]         2014    Urothelial cell carcinoma         Taiwan    Asian       HB         7     169             57                 7        346             171   35    TaqMan     0.03
           Su et al[@b50-ott-11-851]         2015    Oral squamous cell cancer         Taiwan    Asian       HB         7     356             200                20       346             171   35    TaqMan     0.03
           Breyer et al[@b42-ott-11-851]     2009    Prostate cancer                   America   Caucasian   PB         8     450             69                 4        420             98    5     Illumina   0.79
           Tao et al[@b51-ott-11-851]        2015    Breast cancer                     China     Asian       PB         8     11              80                 143      7               105   188   SNaPshot   0.08
           Bachmann et al[@b41-ott-11-851]   2005    Prostate cancer                   Germany   Caucasian   PB         8     243             42                 2        78              17    1     SNaPshot   0.95
  *EZH2*   Rs3757441T\>C                                                                                                      TT              TC                 CC       TT              TC    CC               
           Yu et al[@b45-ott-11-851]         2013    Hepatocellular carcinoma          Taiwan    Asian       HB         7     131             80                 9        271             223   58    TaqMan     0.23
           Wang et al[@b46-ott-11-851]       2014    Colorectal cancer                 China     Asian       HB         7     196             230                86       245             248   53    PCR-RFLP   0.39
           Yu et al[@b47-ott-11-851]         2014    Urothelial cell carcinoma         Taiwan    Asian       HB         7     123             88                 22       271             223   58    TaqMan     0.23
           Ma et al[@b48-ott-11-851]         2014    Esophageal squamous cell cancer   China     Asian       HB         7     112             260                104      147             267   78    PCR-RFLP   0.43
           Su et al[@b50-ott-11-851]         2015    Oral squamous cell cancer         Taiwan    Asian       HB         7     312             221                43       271             223   58    TaqMan     0.23
           Yoon et al[@b43-ott-11-851]       2010    Lung cancer                       Korea     Asian       PB         8     193             125                17       169             134   32    Illumina   0.47
           Zhou et al[@b44-ott-11-851]       2012    Gastric cancer                    China     Asian       PB         7     181             112                18       235             162   28    Sequenom   0.99
           Tao et al[@b51-ott-11-851]        2015    Breast cancer                     China     Asian       PB         8     127             91                 16       144             129   27    SNaPshot   0.80
           Chang et al[@b52-ott-11-851]      2016    Bladder cancer                    China     Asian       PB         8     169             172                34       165             168   42    PCR-RFLP   0.94
  *EZH2*   Rs41277434A\>C                                                                                                     AA              AC                 CC       AA              AC    CC               
           Yu et al[@b45-ott-11-851]         2013    Hepatocellular carcinoma          Taiwan    Asian       HB         7     209             11                 0        517             34    1     TaqMan     0.58
           Wang et al[@b46-ott-11-851]       2014    Colorectal cancer                 China     Asian       HB         7     193             236                83       212             248   86    PCR-RFLP   0.34
           Yu et al[@b47-ott-11-851]         2014    Urothelial cell carcinoma         Taiwan    Asian       HB         7     218             15                 0        517             34    1     TaqMan     0.58
           Ma et al[@b48-ott-11-851]         2014    Esophageal squamous cell cancer   China     Asian       HB         7     133             242                101      141             231   120   PCR-RFLP   0.19
           Su et al[@b50-ott-11-851]         2015    Oral squamous cell cancer         Taiwan    Asian       HB         7     540             35                 1        517             34    1     TaqMan     0.58
           Yoon et al[@b43-ott-11-851]       2010    Lung cancer                       Korea     Asian       PB         8     293             40                 2        298             36    1     Illumina   0.94
           Chang et al[@b52-ott-11-851]      2016    Bladder cancer                    China     Asian       PB         8     215             98                 62       220             96    59    PCR-RFLP   5.6E-13

**Abbreviations:** HB, hospital-based controls; HWE, Hardy--Weinberg equilibrium; Illumina, Illumina GoldenGate platform; NOS, Newcastle--Ottawa Quality Assessment Scale; PB, population-based controls; PCR-RFPL, polymerase chain reaction-restriction fragment length polymorphism; SNaPshot, multiplex-PCR SNaPshot assay; SNP, single nucleotide polymorphism; TaqMan, TaqMan Real-Time PCR Assays.
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###### 

Forest plot for the relationship between rs887569 and cancer risk: (**A**) CT/CC; (**B**) TT/CC; (**C**) CTTT/CC; (**D**) TT/CCCT.

**Note:** Weights are from random effects analysis.
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![Forest plot for the relationship between rs2302427 and cancer risk: (**A**) CG/CC; (**B**) GG/CC; (**C**) CGGG/CC; (**D**) GG/CCCG.\
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###### 

Characteristics of studies included in the meta-analysis

  First author                      Years   Cancer type                          Region    Ethnicity   Methods    Controls   Case   Control   Polymorphism site                            HWE   NOS
  --------------------------------- ------- ------------------------------------ --------- ----------- ---------- ---------- ------ --------- -------------------------------------------- ----- -----
  Bachmann et al[@b19-ott-11-851]   2005    Prostate cancer                      Germany   Caucasian   SNaPshot   PB         287    96        rs2302427                                    Yes   8
  Breyer et al[@b20-ott-11-851]     2009    Prostate cancer                      America   Caucasian   Illumina   PB         523    523       rs2302427                                    Yes   8
  Yoon et al[@b21-ott-11-851]       2010    Lung cancer                          Korea     Asian       Illumina   PB         335    335       rs887569, rs2302427, rs3757441, rs41277434   Yes   8
  Zhou et al[@b22-ott-11-851]       2014    Gastric cancer                       China     Asian       Sequenom   PB         311    425       rs3757441                                    Yes   8
  Yu et al[@b23-ott-11-851]         2013    Hepatocellular carcinoma             Taiwan    Asian       TaqMan     HB         220    552       rs2302427, rs3757441, rs41277434             Yes   7
  Wang et al[@b24-ott-11-851]       2014    Colorectal cancer                    China     Asian       PCR-RFLP   HB         512    576       rs887569, rs3757441, rs41277434              Yes   7
  Yu et al[@b25-ott-11-851]         2014    Urothelial cell carcinoma            Taiwan    Asian       TaqMan     HB         233    552       rs2302427, rs3757441, rs41277434             Yes   7
  Ma et al[@b26-ott-11-851]         2014    Esophageal squamous cell carcinoma   China     Asian       PCR-RFLP   HB         476    492       rs887569, rs3757441, rs41277434              Yes   7
  Huang et al[@b27-ott-11-851]      2015    Colorectal cancer                    China     Asian       PCR-RFLP   PB         96     100       rs887569                                     Yes   8
  Su et al[@b28-ott-11-851]         2015    Oral squamous cell cancer            Taiwan    Asian       TaqMan     HB         576    552       rs2302427, rs3757441, rs41277434             Yes   7
  Tao et al[@b29-ott-11-851]        2015    Breast cancer                        China     Asian       SNaPshot   PB         234    300       rs2302427, rs3757441                         Yes   8
  Chang et al[@b30-ott-11-851]      2016    Bladder cancer                       Taiwan    Asian       PCR-RFLP   PB         375    375       rs887569, rs3757441, rs41277434              Yes   8

**Abbreviations:** HB, hospital-based controls; HWE, Hardy--Weinberg equilibrium; Illumina, Illumina GoldenGate platform; NOS, Newcastle--Ottawa Quality Assessment Scale; PB, population-based controls; PCR-RFPL, polymerase chain reaction-restriction fragment length polymorphism; Sequenom, Sequenom MassARRAY iPLEX platform; SNaPshot, multiplex-PCR SNaPshot assay; TaqMan, TaqMan Real-Time PCR Assays.

###### 

Analysis of associations between SNPs of *EZH2* and cancer risk

  Comparisons       Study             N[a](#tfn2-ott-11-851){ref-type="table-fn"}   Cases/controls   WM vs WW[b](#tfn3-ott-11-851){ref-type="table-fn"}   *P*-value[c](#tfn4-ott-11-851){ref-type="table-fn"}   *I*^2^, %   MM vs WW[b](#tfn3-ott-11-851){ref-type="table-fn"}   *P*-value[c](#tfn4-ott-11-851){ref-type="table-fn"}   *I*^2^, %   WM + MM vs WW[b](#tfn3-ott-11-851){ref-type="table-fn"}   *P*-value[c](#tfn4-ott-11-851){ref-type="table-fn"}   *I*^2^, %   MM vs WM + WW[b](#tfn3-ott-11-851){ref-type="table-fn"}   *P*-value[c](#tfn4-ott-11-851){ref-type="table-fn"}   *I*^2^, %
  ----------------- ----------------- --------------------------------------------- ---------------- ---------------------------------------------------- ----------------------------------------------------- ----------- ---------------------------------------------------- ----------------------------------------------------- ----------- --------------------------------------------------------- ----------------------------------------------------- ----------- --------------------------------------------------------- ----------------------------------------------------- -----------
  rs887569 C\>T     Overall (Asian)   5                                             1,794/1,878      0.889 (0.771 to 1.026)                               0.466                                                 0.0         0.738 (0.520 to 1.047)                               0.058                                                 56.2        **0.849 (0.740** to **0.973)**                            **0.29**                                              **19.6**    **0.793 (0.654** to **0.962)**                            **0.162**                                             **38.9**
   Cancer type      DSC               3                                             1,084/1,168      0.923 (0.764 to 1.115)                               0.260                                                 25.7        0.878 (0.533 to 1.445)                               0.068                                                 62.8        0.894 (0.746 to 1.071)                                    0.179                                                 41.9        0.877 (0.696 to 1.104)                                    0.186                                                 40.6
  rs2302427 C\>G    Overall           7                                             2,408/2,910      0.866 (0.696 to 1.077)                               0.051                                                 52.0        **0.562 (0.400** to **0.792)**                       **0.967**                                             **0.0**     **0.856 (0.748** to **0.980)**                            **0.089**                                             **45.4**    **0.733 (0.571** to **0.940)**                            **0.621**                                             **0.0**
   Ethnicity        Asian             5                                             1,598/2,291      0.937 (0.733 to 1.197)                               0.093                                                 49.8        **0.550 (0.384** to **0.787)**                       **0.881**                                             **0.0**     0.911 (0.782 to 1.061)                                    0.098                                                 49.0        **0.731 (0.566** to **0.944)**                            **0.356**                                             **0.0**
                    Caucasian         2                                             810/619          **0.686 (0.511** to **0.921)**                       **0.601**                                             **0.0**     0.723 (0.226 to 2.313)                               0.914                                                 0.0         **0.688 (0.515** to **0.917)**                            **0.627**                                             **0.0**     0.768 (0.240 to 2.456)                                    0.898                                                 0.0
   Cancer type      DSC               2                                             796/1,104        1.132 (0.925 to 1.385)                               0.958                                                 0.0         **0.618 (0.394** to **0.970)**                       **0.558**                                             **0.0**     1.045 (0.862 to 1.267)                                    0.927                                                 0.0         **0.593 (0.380** to **0.925)**                            **0.547**                                             **0.0**
                    USC               3                                             1,033/1,362      **0.684 (0.546** to **0.857)**                       **0.872**                                             **0.0**     **0.484 (0.248** to **0.943)**                       **0.733**                                             **0.0**     **0.664 (0.534** to **0.826)**                            **0.837**                                             **0.0**     0.533 (0.274 to 1.035)                                    0.769                                                 0.0
  rs3757441 T\>C    Overall (Asian)   9                                             3,272/4,159      0.938 (0.849 to 1.036)                               0.202                                                 27.2        0.827 (0.555 to 1.231)                               0.000                                                 81.3        0.915 (0.774 to 1.081)                                    0.002                                                 67.0        0.846 (0.599 to 1.193)                                    0.000                                                 77.6
   Cancer type      DSC               5                                             2,905/2,579      0.947 (0.806 to 1.177)                               0.068                                                 54.2        0.947 (0.513 to 1.748)                               0.000                                                 87.7        0.976 (0.743 to 1.282)                                    0.001                                                 80.0        0.946 (0.562 to 1.592)                                    0.000                                                 85.0
                    USC               2                                             608/927          0.937 (0.751 to 1.169)                               0.538                                                 0.0         0.811 (0.563 to 1.170)                               0.881                                                 0.0         0.912 (0.739 to 1.125)                                    0.625                                                 0.0         0.817 (0.575 to 1.160)                                    0.845                                                 0.0
  rs41277434 A\>C   Overall (Asian)   7                                             2,727/3,403      1.050 (0.908 to 1.213)                               0.990                                                 0.0         1.044 (0.812 to 1.240)                               0.986                                                 0.0         1.037 (0.905 to 1.187)                                    0.988                                                 0.0         0.957 (0.791 to 1.158)                                    0.948                                                 0.0
   Cancer type      DSC               4                                             1,784/2,172      1.041 (0.872 to 1.242)                               0.855                                                 0.0         0.971 (0.755 to 1.247)                               0.928                                                 0.0         1.017 (0.860 to 1.203)                                    0.881                                                 0.0         0.920 (0.738 to 1.148)                                    0.827                                                 0.0
                    USC               2                                             608/927          1.045 (0776 to 1.408)                                0.996                                                 0.0         1.705 (0.717 to 1.595)                               0.851                                                 0.0         1.049 (0.807 to 1.365)                                    0.913                                                 0.0         1.056 (0.718 to 1.554)                                    0.856                                                 0.0

**Notes:**

Number of comparisons;

W, major allele; M, minor allele.

*P*-value of *Q*-test of heterogeneity test. DSCs, including hepatocellular carcinoma, oral squamous cell cancer, colorectal cancer, esophageal squamous cell carcinoma, or gastric cancer; USCs, including urothelial cell carcinoma, prostate cancer, bladder cancer. Random-effects models were used if heterogeneity between articles was reported (*P*\<0.10, *I*^2^\>50%), otherwise fixed-effects models were applied. WM, WW, MM represent heterozygote, homozygote for major allele and homozygote for minor allele, respectively. Bold data is statistically significant.

**Abbreviations:** DSC, digestive system cancer; USC, urogenital system cancer.

###### 

Publication bias in meta-analysis for each inheritance model

  SNPs                               Inheritance model              Studies   Begg's test   Egger's test                           
  ---------------------------------- ------------------------------ --------- ------------- ------------------- ------------------ -------
  rs887569 C\>T                      Heterozygote genotype: CT/CC   5         0.73          0.462               (−0.54 to 5.08)    0.082
  Homozygote genotype: TT/CC         5                              0.24      0.806         (−9.31 to 10.11)    0.904              
  Dominant genetic model: CTTT/CC    5                              0.73      0.462         (−1.75 to 6.47)     0.165              
  Recessive genetic model: TT/CCCT   5                              0.24      0.806         (−10.84 to 5.23)    0.328              
  rs2302427 C\>G                     Heterozygote genotype: CG/CC   7         0.60          0.548               (−5.94 to 1.95)    0.250
  Homozygote genotype: GG/CC         7                              0.00      1.000         (−1.08 to 1.44)     0.729              
  Dominant genetic model: CGGG/CC    7                              1.20      0.230         (−5.41 to 2.10)     0.308              
  Recessive genetic model: GG/CCCG   7                              0.30      0.764         (−2.24 to 0.91)     0.328              
  rs3757441 T\>C                     Heterozygote genotype: CT/TT   9         1.98          0.048               (−11.99 to 3.87)   0.265
  Homozygote genotype: CC/TT         9                              1.77      0.076         (−13.17 to −2.36)   0.012              
  Dominant genetic model: CCCT/TT    9                              1.77      0.076         (−17.25 to 5.26)    0.268              
  Recessive genetic model: CC/CTTT   9                              1.36      0.175         (−10.34 to −2.11)   0.009              
  rs41277434 A\>C                    Heterozygote genotype: AC/AA   7         0.90          0.368               (−1.66 to 0.47)    0.212
  Homozygote genotype: CC/AA         7                              2.10      0.035         (−0.10 to 1.17)     0.083              
  Dominant genetic model: ACCC/AA    7                              1.20      0.230         (−1.56 to 0.54)     0.263              
  Recessive genetic model: CC/AAAC   7                              2.10      0.035         (−0.18 to 1.38)     0.106              

**Abbreviation:** SNP, single nucleotide polymorphism.

[^1]: These authors contributed equally to this work
